Acute Hepatic Porphyria Diagnosis and Management

Clinical Presentation and Diagnosis

The American Association for the Study of Liver Diseases recommends suspecting acute hepatic porphyria in patients with recurrent severe abdominal pain without an identifiable cause, especially in women aged 15-50 years 1, 2
Neuropsychiatric symptoms, including peripheral neuropathy, motor weakness, or psychiatric manifestations, can be a presenting feature of acute hepatic porphyria 3, 4
Hyponatremia occurs in 25-60% of acute attacks 5
Symptoms can be triggered by specific medications, fasting, alcohol, stress, or hormonal changes 3, 6

The American Gastroenterological Association recommends ordering a random spot urine for ALA, PBG, and creatinine immediately when acute porphyria is suspected 1, 8, 2
Normal urine PBG excludes acute hepatic porphyria as the cause of current symptoms 5, 2
PBG >10 mg/g creatinine (or >5-fold upper limit of normal) confirms acute hepatic porphyria 1, 8, 2

The American Association for the Study of Liver Diseases classifies patients into four subgroups that determine monitoring frequency: latent genetic carriers, asymptomatic high excretors, sporadic attack patients, and recurrent attack patients 3, 6
Every patient with confirmed acute hepatic porphyria requires at least annual monitoring, including liver enzymes, creatinine, and eGFR 1, 8, 2
Recurrent attack patients require closer follow-up with monitoring tailored to attack frequency and complications 3, 6
Patients on prophylactic hemin or givosiran require additional monitoring, including comprehensive metabolic panel, plasma homocysteine, B12/folate levels, and amylase/lipase 1, 8, 3, 5

Screen for chronic kidney disease, hepatocellular carcinoma, hypertension, osteoporosis and vitamin D deficiency, and anemia 3, 4, 6, 7

Women of childbearing age should receive pre-conception evaluation, high-risk obstetrical care during pregnancy, and careful contraceptive selection to avoid triggering attacks 6, 7
All newly diagnosed patients must receive education about avoiding triggering factors, including porphyrinogenic drugs, fasting, alcohol, smoking, and stress management 3, 6